

PATENT

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

22154 U.S. PTO
10/666756
09/18/03

Sir:

Transmitted herewith for filing is the patent application
under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: MO1375 US CNT 4
INVENTORS: **James R. McCarthy; Michael L.
Edwards; Donald P. Matthews**
TITLE: **NOVEL 2'-HALOMETHYLIDENE, 2'-
ETHENYLIDENE AND 2'-ETHYNYL CYTIDINE,
URIDINE AND GUANOSINE DERIVATIVES**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, Washington, D.C. 20231,
on

18 September 2003
Date of Deposit
Benita Walker
Signature

EV 105232494 US
Express Mail No.

APPLICATION ELEMENTS

1. ☒ *Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)

2. ☒ Specification
(preferred arrangement set forth below)
- Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure

Total Pages

3. ☐ Drawing(s) (35 U.S.C. 113)

Total Sheets

4. Oath or Declaration

Total Pages

- a. ☐ Newly executed (original or copy)

- b. ☒ Copy from a prior application (37 CFR § 1.63(d))
(for continuation/divisional with Box 16 completed)

- i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior
application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).

5. ☐ Microfiche Computer Program (Appendix)

6. Nucleotide and/or Amino Acid Sequence Submission

(if applicable, all necessary)

- a. ☐ Computer Readable Copy
b. ☐ Paper Copy (identical to computer copy)
c. ☐ Statement verifying identity of above copies

☒ If a **CONTINUING Application**, check appropriate box, and supply the requisite information:

☒ Continuation ☐ Divisional ☐ Continuation-in-part

of prior application no: 10/164,848, filed June 6, 2002,

Examiner Crane, Group/Art Unit 1623.

(The cross reference has been/will be inserted on page one of the specification).

☐ This application claims the benefit of U.S. Provisional Application No. _____,
filed _____. (The cross reference has been/will be inserted on page one of the specification).

☒ **Incorporation By Reference** (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.)

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ACCOMPANYING APPLICATION PARTS


7. ☐ Assignment Papers (cover sheet & document(s))
8. ☐ 37 CFR §3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
9. ☐ English Translation Document (if applicable)
10. ☐ Information Disclosure ☐ Copies of IDS
Statement (IDS)/PTO-1449 Citations
11. ☒ Preliminary Amendment
12. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
13. ☐ *Small Entity Statement(s) ☐ Statement filed in prior application,
(PTO/SB/09-12) Status still proper and desired
14. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
15. ☒ Other: E-PAVE; Copy of Declaration; Copy of Extension of
Time MO1375USCNT 3

CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label

005487

(Insert Customer No. or Attach bar code label here)



Mark C. Nelligan, Reg. No. 36,389
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-2388
Telefax (908) 231-2626
Aventis Docket No. MO 1375 US CNT 4

09/18/03
15138 U.S. PTO

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

Complete if Known

Application Number	NOT YET ASSIGNED
Filing Date	FILED HEREWITH
First Named Inventor	James R. McCarthy et al
Examiner Name	Lawrence E. Crane
Group / Art Unit	1623
Attorney Docket No.	MO1375 US CNT 4

TOTAL AMOUNT OF PAYMENT (\$ 750.00)

METHOD OF PAYMENT (check all that apply)		FEE CALCULATION (continued)	
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card	3. ADDITIONAL FEES	
<input type="checkbox"/> Money Order	<input type="checkbox"/> Other		
<input type="checkbox"/> None			
<input checked="" type="checkbox"/> Deposit Account			
Deposit Account Number	18-1982		
Deposit Account Name	Aventis Pharmaceuticals Inc.		
The Commissioner is authorized to: (check all that apply)			
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Credit any overpayments		
<input checked="" type="checkbox"/> Charge any additional fee(s) during the pendency of this application			
<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account			
FEE CALCULATION			
1. BASIC FILING FEE			
Large Entity	Small Entity		
Fee Code	Fee (\$)	Fee Code	Fee (\$)
1001	750	2001	375
1002	330	2002	165
1003	520	2003	260
1004	750	2004	375
1005	160	2005	80
SUBTOTAL (1)		(\$750.00)	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE			
Total Claims	1	-20**=	0
Independent Claims	1	-3**=	0
Multiple Dependent			
Large Entity	Small Entity		
Fee Code	Fee (\$)	Fee Code	Fee (\$)
1202	18	2202	9
1201	84	2201	42
1203	280	2203	140
1204	84	2204	42
1205	18	2205	9
SUBTOTAL (2)		(\$750.00)	
**or number previously paid, if greater; For Reissues, see above			
		3. ADDITIONAL FEES	
		Large Entity	Small Entity
		Fee Code	Fee (\$)
		1051	130
		1052	50
		1053	130
		1812	2,520
		1804	920*
		1805	1,840*
		1251	110
		1252	410
		1253	930
		1254	1,450
		1255	1970
		1401	320
		1402	320
		1403	280
		1451	1,510
		1452	110
		1453	1,300
		1501	1,300
		1502	470
		1503	630
		1460	130
		1807	50
		1806	180
		8021	40
		1809	750
		1810	750
		1801	750
		1802	900
		Other fee (specify)	
		SUBTOTAL (3)	
		(\$)	

SUBMITTED BY		Complete (If applicable)	
Name (Print/Type)	Mark C. Nelligan, R. g. No. 36,389	Registration No. (Attorney/Agent)	36,389
Signature	<i>Mark C. Nelligan</i>	Telephone	(908) 231-2388
		Date	September 18, 2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Aventis Pharmaceuticals Inc. template